S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Options Trading Plan–Perfect For Beginners (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Options Trading Plan–Perfect For Beginners (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Options Trading Plan–Perfect For Beginners (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
NASDAQ:MBRX

Moleculin Biotech (MBRX) Stock Forecast, Price & News

$0.39
-0.03 (-7.14%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.38
$0.43
50-Day Range
$0.38
$0.68
52-Week Range
$0.34
$1.65
Volume
62,074 shs
Average Volume
111,550 shs
Market Capitalization
$11.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Moleculin Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,592.3% Upside
$10.50 Price Target
Short Interest
Healthy
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.07mentions of Moleculin Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

344th out of 968 stocks

Pharmaceutical Preparations Industry

145th out of 445 stocks


MBRX stock logo

About Moleculin Biotech (NASDAQ:MBRX) Stock

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

MBRX Price History

MBRX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com
Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Maxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX)
Q2 2023 Moleculin Biotech Inc Earnings Call
Houston Biotech News
Moleculin Reports Second Quarter 2023 Financial Results
Earnings Preview For Moleculin Biotech
Maxim Group Reaffirms Their Buy Rating on Moleculin Biotech (MBRX)
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Company Calendar

Last Earnings
8/11/2023
Today
9/23/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBRX
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+2,592.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-29,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.82 per share

Miscellaneous

Free Float
27,813,000
Market Cap
$11.63 million
Optionable
Not Optionable
Beta
1.97
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Walter V. Klemp (Age 63)
    Founder, Chairman, Pres & CEO
    Comp: $1.35M
  • Mr. Jonathan P. Foster CPA (Age 59)
    Exec. VP & CFO
    Comp: $653.69k
  • Dr. Donald H. Picker Ph.D. (Age 77)
    Chief Scientific Officer
    Comp: $520.84k
  • Dr. Waldemar Priebe Ph.D.
    Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP (Age 71)
    M.D., F.A.C.P., Chief Medical Officer of Annamycin
  • Dr. John Paul Waymack M.D. (Age 71)
    Sc.D., Sr. Chief Medical Officer
  • Dr. Sandra L. Silberman M.D. (Age 68)
    Ph.D., Chief Medical Officer of New Products
  • Dr. Wolfram C. M. Dempke M.B.A.
    M.D., Ph.D., European Chief Medical Officer
  • Ms. Jacqueline Northcut (Age 61)
    Consultant
  • Mr. Louis Ploth Jr. (Age 69)
    Independent Advisor













MBRX Stock - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings
or view top-rated stocks.

What is Moleculin Biotech's stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Moleculin Biotech's stock. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 2,592.3% from the stock's current price.
View analysts price targets for MBRX
or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2023?

Moleculin Biotech's stock was trading at $1.06 on January 1st, 2023. Since then, MBRX shares have decreased by 63.2% and is now trading at $0.39.
View the best growth stocks for 2023 here
.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 38,100 shares, a decrease of 75.4% from the August 15th total of 155,100 shares. Based on an average daily volume of 164,900 shares, the days-to-cover ratio is presently 0.2 days.
View Moleculin Biotech's Short Interest
.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MBRX earnings forecast
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.08. During the same quarter in the previous year, the firm posted ($0.24) earnings per share.

When did Moleculin Biotech's stock split?

Shares of Moleculin Biotech reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

Who are Moleculin Biotech's major shareholders?

Moleculin Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.66%) and Renaissance Technologies LLC (0.43%).
View institutional ownership trends
.

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $0.39.

How much money does Moleculin Biotech make?

Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $11.63 million. The company earns $-29,020,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.

This page (NASDAQ:MBRX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -